JP2018522046A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522046A5
JP2018522046A5 JP2018505695A JP2018505695A JP2018522046A5 JP 2018522046 A5 JP2018522046 A5 JP 2018522046A5 JP 2018505695 A JP2018505695 A JP 2018505695A JP 2018505695 A JP2018505695 A JP 2018505695A JP 2018522046 A5 JP2018522046 A5 JP 2018522046A5
Authority
JP
Japan
Prior art keywords
chloro
substituted
phenyl
triazol
oxopyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505695A
Other languages
English (en)
Japanese (ja)
Other versions
JP6785838B2 (ja
JP2018522046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045276 external-priority patent/WO2017023992A1/en
Publication of JP2018522046A publication Critical patent/JP2018522046A/ja
Publication of JP2018522046A5 publication Critical patent/JP2018522046A5/ja
Application granted granted Critical
Publication of JP6785838B2 publication Critical patent/JP6785838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505695A 2015-08-05 2016-08-03 新規な置換グリシン誘導のfxia阻害剤 Active JP6785838B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201267P 2015-08-05 2015-08-05
US62/201,267 2015-08-05
PCT/US2016/045276 WO2017023992A1 (en) 2015-08-05 2016-08-03 Novel substituted glycine derived fxia inhibitors

Publications (3)

Publication Number Publication Date
JP2018522046A JP2018522046A (ja) 2018-08-09
JP2018522046A5 true JP2018522046A5 (enExample) 2019-09-12
JP6785838B2 JP6785838B2 (ja) 2020-11-18

Family

ID=56618292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505695A Active JP6785838B2 (ja) 2015-08-05 2016-08-03 新規な置換グリシン誘導のfxia阻害剤

Country Status (7)

Country Link
US (2) US10336730B2 (enExample)
EP (1) EP3331872B1 (enExample)
JP (1) JP6785838B2 (enExample)
KR (1) KR102697816B1 (enExample)
CN (1) CN108137549B (enExample)
ES (1) ES2754599T3 (enExample)
WO (1) WO2017023992A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6742348B2 (ja) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのジアミド大員環
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
JP6629958B2 (ja) 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アルキルまたはシクロアルキルP2’基を担持する大員環の第XIa因子阻害剤
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
JP7112715B2 (ja) * 2018-03-23 2022-08-04 株式会社Kyulux 有機発光素子材料合成用原料および化合物
WO2020007256A1 (zh) 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
MX2021000256A (es) * 2018-07-19 2021-03-25 Jiangsu Hengrui Medicine Co Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
CN112047931B (zh) * 2019-06-06 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途
CN112341377B (zh) * 2019-08-09 2024-05-14 上海美悦生物科技发展有限公司 一种杂环类化合物及其应用
US20230027295A1 (en) * 2019-09-27 2023-01-26 Shenzhen Salubris Pharmaceuticals Co., Ltd. Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
CN113005176A (zh) * 2019-12-20 2021-06-22 深圳市帝迈生物技术有限公司 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
JP7700218B2 (ja) * 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
TW202222315A (zh) * 2020-10-23 2022-06-16 大陸商深圳信立泰藥業股份有限公司 FXIa抑制劑化合物的鹽、包括其的藥物組合物及其用途
WO2022083707A1 (zh) * 2020-10-23 2022-04-28 深圳信立泰药业股份有限公司 FXIa抑制剂化合物或其盐的医药用途
CN112679446A (zh) * 2020-10-26 2021-04-20 都创(上海)医药科技有限公司 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法
WO2022122035A1 (zh) * 2020-12-11 2022-06-16 上海领泰生物医药科技有限公司 凝血因子XIa抑制剂及其制备方法和应用
CN112675173B (zh) * 2020-12-25 2022-04-05 华南理工大学 FXIa抑制剂化合物或其盐的医药用途
CN115461330A (zh) * 2021-03-18 2022-12-09 深圳信立泰药业股份有限公司 FXIa抑制剂化合物杂质及其制备方法和用途
CN116283750B (zh) * 2021-09-09 2025-02-07 成都泰和伟业生物科技有限公司 一种杂环酰胺类衍生物及其制备方法和用途
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
AU2024309220A1 (en) 2023-06-30 2026-01-29 Shenzhen Salubris Pharmaceuticals Co., Ltd Polysubstituted macrocyclic compound, and preparation method therefor and use thereof
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008086A (en) * 1972-04-15 1977-02-15 Konishiroku Photo Industry Co., Ltd. Silver halide emulsion containing photographic yellow coupler
DE2318807C2 (de) 1972-04-15 1982-05-27 Konishiroku Photo Industry Co., Ltd., Tokyo Farbphotographisches Aufzeichnungsmaterial und Farbentwickler zum Entwickeln desselben
ATE27T1 (de) 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPS57501328A (enExample) * 1980-08-07 1982-07-29
AU1595997A (en) 1996-01-26 1997-08-20 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
EP1427415B1 (en) 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2506114A1 (en) 2002-12-05 2004-06-24 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
KR20050092373A (ko) 2002-12-24 2005-09-21 다이이찌 세이야꾸 가부시기가이샤 신규한 에틸렌디아민 유도체
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
WO2005061462A2 (en) 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
WO2006090234A1 (en) 2005-02-22 2006-08-31 Ranbaxy Laboratories Limited Heterocyclic derivatives as cell adhesion inhibitors
EP1973546B1 (en) 2005-12-30 2012-06-13 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
CA2670726A1 (en) 2006-12-07 2008-06-19 Novartis Ag 6-oxo-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
EP2125750B1 (en) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009078498A1 (en) 2007-12-17 2009-06-25 Green Cross Corporation Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PE20091653A1 (es) 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP2010280638A (ja) 2009-06-08 2010-12-16 Nippon Nohyaku Co Ltd ハロアルキルスルホンアニリド誘導体又はその塩類及びこれを有効成分とする除草剤並びにその使用方法
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2013056034A1 (en) * 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
DK2794597T3 (en) 2011-12-21 2018-01-15 Ono Pharmaceutical Co PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
PT2880026T (pt) * 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
CN104955806B (zh) 2013-02-06 2018-09-14 默克专利股份公司 用于治疗骨关节炎的作为聚蛋白聚糖酶抑制剂的取代羧酸衍生物
US9809545B2 (en) * 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂

Similar Documents

Publication Publication Date Title
JP2022533120A5 (enExample)
AU2016240033B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
AU2022201352A1 (en) Pyrazole derivatives as MALT1 inhibitors
JP2019504821A5 (enExample)
TWI494314B (zh) 5,7-取代的-咪唑并[1,2-c]嘧啶
JP2020514267A5 (enExample)
EP2566477B1 (en) Amino-quinolines as kinase inhibitors
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CA2775475C (en) Pyridinylimidazolone derivatives for the inhibition of pi3 kinases
HUE032770T2 (en) Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
JP2014521711A5 (enExample)
JP2016500671A5 (enExample)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
US10023576B2 (en) Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
JP2022500402A5 (enExample)
US20120041024A1 (en) Quinolyl amines as kinase inhibitors
RU2013120966A (ru) ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
RU2017105296A (ru) Новые соединения
WO2015015318A4 (en) Novel quinazolinones as bromodomain inhibitors
CZ20031676A3 (en) Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors
PT2081937E (pt) Moduladores de proteína-cinase de triazolo-piridazina
ES2550201T3 (es) Moduladores de la PDE10
HRP20250272T1 (hr) Derivati benzimidazola i njihova uporaba
CN114945571A (zh) 环状化合物及其使用方法
RU2014119244A (ru) Гетероциклические соединения и способы их использования